Theralase Technologies Inc. (CVE:TLT – Get Free Report) traded up 2.1% during trading on Tuesday . The company traded as high as C$0.24 and last traded at C$0.24. Approximately 47,802 shares changed hands during trading, a decline of 83% from the average session volume of 273,888 shares. The stock had previously closed at C$0.23.
Theralase Technologies Price Performance
The firm has a market cap of C$68.00 million, a PE ratio of -16.43 and a beta of -0.41. The firm’s fifty day simple moving average is C$0.26 and its two-hundred day simple moving average is C$0.25. The company has a quick ratio of 3.40, a current ratio of 1.37 and a debt-to-equity ratio of 22.13.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Read More
- Five stocks we like better than Theralase Technologies
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
